Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for elisa i. Barchuk
Your search for Alisa I. Barchuk retrieved no results
COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
Barchuk A, Skougarevskiy D, Kouprianov A, Shirokov D, Dudkina O, Tursun-Zade R, Sergeeva M, Tychkova V, Komissarov A, Zheltukhina A, Lioznov D, Isaev A, Pomerantseva E, Zhikrivetskaya S, Sofronova Y, Blagodatskikh K, Titaev K, Barabanova L, Danilenko D. Barchuk A, et al. PLoS One. 2022 Jun 15;17(6):e0266945. doi: 10.1371/journal.pone.0266945. eCollection 2022. PLoS One. 2022. PMID: 35704649 Free PMC article.
Petersburg recruited with the random digit dialing (RDD), accompanied by a telephone interview to collect information on both individuals who accepted and declined the invitation for testing and account for non-response. We have used enzyme-linked immunosorbent …
Petersburg recruited with the random digit dialing (RDD), accompanied by a telephone interview to collect information on both individuals wh …
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study.
Barchuk A, Skougarevskiy D, Titaev K, Shirokov D, Raskina Y, Novkunkskaya A, Talantov P, Isaev A, Pomerantseva E, Zhikrivetskaya S, Barabanova L, Volkov V. Barchuk A, et al. Sci Rep. 2021 Jun 21;11(1):12930. doi: 10.1038/s41598-021-92206-y. Sci Rep. 2021. PMID: 34155259 Free PMC article.
Naive seroprevalence corrected for test characteristics was 9.0% (7.2-10.8) by CMIA and 10.5% (8.6-12.4) by ELISA. Correction for non-response decreased estimates to 7.4% (5.7-9.2) and 9.1% (7.2-10.9) for CMIA and ELISA, respectively. ...
Naive seroprevalence corrected for test characteristics was 9.0% (7.2-10.8) by CMIA and 10.5% (8.6-12.4) by ELISA. Correction for non …
Spinal HMGB1 participates in the early stages of paclitaxel-induced neuropathic pain via microglial TLR4 and RAGE activation.
Moraes TR, Veras FP, Barchuk AR, Nogueira ESC, Kanashiro A, Galdino G. Moraes TR, et al. Front Immunol. 2024 Feb 7;15:1303937. doi: 10.3389/fimmu.2024.1303937. eCollection 2024. Front Immunol. 2024. PMID: 38384464 Free PMC article.
Microglia, astrocytes, glial cells, RAGE, and TLR4 protein expression were analyzed by Western blot. ELISA immunoassay was also used to assess HMGB1, IL-1beta, and TNF-alpha spinal levels. ...
Microglia, astrocytes, glial cells, RAGE, and TLR4 protein expression were analyzed by Western blot. ELISA immunoassay was also used …
Evaluation of the performance of SARS--CoV--2 antibody assays for a longitudinal population-based study of COVID--19 spread in St. Petersburg, Russia.
Barchuk A, Shirokov D, Sergeeva M, Tursun Zade R, Dudkina O, Tychkova V, Barabanova L, Skougarevskiy D, Danilenko D. Barchuk A, et al. J Med Virol. 2021 Oct;93(10):5846-5852. doi: 10.1002/jmv.27126. Epub 2021 Jun 12. J Med Virol. 2021. PMID: 34081328 Free PMC article.
We validated three different antibody assays: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS--CoV--2 immunoglobulin G (IgG), enzyme- linked immunosorbent assay (ELISA) CoronaPass total antibodies test, and ELISA S …
We validated three different antibody assays: chemiluminescent microparticle immunoassay (CMIA) Abbott Architect SARS--CoV--2 immunoglobulin …